The tests have been carried out by Cannabics Pharmaceuticals at the company’s High Through-put Screening (HTS) facility in Israel. The tests have shown that the cannabinoids and CBG (Cannabigerol) both exhibit anti-tumour properties after being tested on human Gastrointestinal Cancer Cells.
CBG is a non-psychoactive cannabinoid and is one of the naturally occurring phyto-cannabinoids, bearing a host of potential positive therapeutic qualities and may promote antimicrobial (stops the growth or kills microorganisms), anti‐inflammatory, pain relief, and neurogenesis activity (running, swimming ect.).
CBG is shown to induce significantly higher rates of necrosis in these cancer cells compared to other cannabinoids.
Dr Yaakov Waksman, the company’s head of cannabidiol research, said: “My working assumption is that these results show that a correlation may exist between a cannabinoid’s Topological Polar Surface Area (TPSA) value and its ability to induce anti-tumour activity, diminishing cancer cell’s viability rates.”
Dr Eyal Ballan, CTO and Co-Founder, added: “Gastrointestinal cancers are amongst the leading and most wide-spread causes of cancer-related deaths worldwide. We are intrigued by the results we have obtained in the lab, and our aim is to consider placing an emphasis on this organ system, and to further explore the differential anti-tumour properties of cannabinoids.
“We believe that these preliminary results vindicate our vision; which is to bring personalisation into cannabinoid-based cancer treatments.”
(running, swimming ect.).
CBG is shown to induce significantly higher rates of necrosis in these cancer cells compared to other cannabinoids.
